Hae K Im
Overview
Explore the profile of Hae K Im including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
163
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Barbeira A, Melia O, Liang Y, Bonazzola R, Wang G, Wheeler H, et al.
Genet Epidemiol
. 2020 Sep;
PMID: 32964524
The integration of transcriptomic studies and genome-wide association studies (GWAS) via imputed expression has seen extensive application in recent years, enabling the functional characterization and causal gene prioritization of GWAS...
2.
Pividori M, Rajagopal P, Barbeira A, Liang Y, Melia O, Bastarache L, et al.
Sci Adv
. 2020 Sep;
6(37).
PMID: 32917697
Large-scale genomic and transcriptomic initiatives offer unprecedented insight into complex traits, but clinical translation remains limited by variant-level associations without biological context and lack of analytic resources. Our resource, PhenomeXcan,...
3.
Stark A, Hause Jr R, Gorsic L, Antao N, Wong S, Chung S, et al.
PLoS Genet
. 2014 Apr;
10(4):e1004192.
PMID: 24699359
Annotating and interpreting the results of genome-wide association studies (GWAS) remains challenging. Assigning function to genetic variants as expression quantitative trait loci is an expanding and useful approach, but focuses...
4.
Gorsic L, Stark A, Wheeler H, Wong S, Im H, Dolan M
PLoS One
. 2013 Dec;
8(12):e82220.
PMID: 24367505
Cisplatin, a commonly used chemotherapeutic, is associated with ototoxicity, renal toxicity and neurotoxicity, thus identifying means to increase the therapeutic index of cisplatin may allow for improved outcomes. A SNP...
5.
Arowolo O, Njiaju U, Ogundiran T, Abidoye O, Lawal O, Obajimi M, et al.
Breast J
. 2013 Jul;
19(5):470-7.
PMID: 23865786
The majority of clinical trials of neo-adjuvant therapy for breast cancer have been conducted in resource-rich countries. We chose Nigeria, a resource-poor country, as the major site for a phase...
6.
Gamazon E, Lamba J, Pounds S, Stark A, Wheeler H, Cao X, et al.
Blood
. 2013 Mar;
121(21):4366-76.
PMID: 23538338
A whole-genome approach was used to investigate the genetic determinants of cytarabine-induced cytotoxicity. We performed a meta-analysis of genome-wide association studies involving 523 lymphoblastoid cell lines (LCLs) from individuals of...